Publication | Open Access
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
60
Citations
32
References
2024
Year
MedicineMelanomaImmunologySeven-year AnalysisImmune Checkpoint InhibitorStage Iii MelanomaDermatologyCancer TreatmentImmunotherapyOncologyRadiation Oncology
| Year | Citations | |
|---|---|---|
Page 1
Page 1